CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -1.83: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
461.45MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
3.26xvs all stocks
52-Week Change
72.56%vs all stocks
Market Capitalization
461.45MUSDvs all stocks (USD)
Enterprise Value
361.48MUSDvs all stocks (USD)
Forward P/E
-1.88xvs Biotechnology peers
Price to Book (MRQ)
2.88xvs Biotechnology peers
Enterprise to EBITDA
-2.03xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-71.58%vs Biotechnology peers
Return on Equity (TTM)
-156.03%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-177.90MUSDvs all stocks (USD)
Net Income (TTM)
-175.43MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-142.84MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-90.82MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-172.24MUSDvs all stocks (USD)
Pre-tax Income
-167.86MUSDFY2025 · Dec 31, 2025Net Income
-167.86MUSDFY2025 · Dec 31, 2025EBIT
-165.85MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-164.21MUSDFY2025 · Dec 31, 2025Research & Development
142.67MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
29.57MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
6.03MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.00MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-167.86MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-134.91MUSDFY2025 · Dec 31, 2025Free Cash Flow
-136.14MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
82.98MUSDFY2025 · Dec 31, 2025Interest Paid
1.71MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-167.86MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.65MUSDFY2025 · Dec 31, 2025Stock-based Compensation
20.94MUSDFY2025 · Dec 31, 2025Other Non-cash Items
15.90MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
1.55MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-7.09MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.23MUSDFY2025 · Dec 31, 2025Purchase of Investments
-99.04MUSDFY2025 · Dec 31, 2025Sale of Investments
50.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-50.27MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-6.26MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
100.04MUSDFY2025 · Dec 31, 2025Shares Outstanding
111.32MSharesUpdated Jul 18, 2026Shares Short
34.06MSharesUpdated Jul 18, 2026Short Ratio
6.07daysvs all stocks
Short % of Shares Outstanding
23.12%vs all stocks
% Held by Insiders
1.00%vs all stocks
% Held by Institutions
64.32%vs all stocks
Total Cash (MRQ)
116.64MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7150USDUpdated Jul 18, 2026Total Debt (MRQ)
26.45MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2560xvs Biotechnology peers
Current Ratio (MRQ)
2.95xvs Biotechnology peers
Book Value per Share (MRQ)
0.9280USDUpdated Jul 18, 2026Total Assets
165.08MUSDvs all stocks (USD)
Total Current Assets
138.87MUSDFY2025 · Dec 31, 2025Total Liabilities
53.03MUSDFY2025 · Dec 31, 2025Total Non-current Assets
26.21MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.88MUSDFY2025 · Dec 31, 2025Total Current Liabilities
50.15MUSDFY2025 · Dec 31, 2025Cash
1.51MUSDFY2025 · Dec 31, 2025Cash Equivalents
81.47MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
82.98MUSDFY2025 · Dec 31, 2025Other Short-term Investments
50.62MUSDFY2025 · Dec 31, 2025Accounts Payable
6.64MUSDFY2025 · Dec 31, 2025Short-term Debt
24.22MUSDFY2025 · Dec 31, 2025Other Current Liabilities
80.00KUSDFY2025 · Dec 31, 2025Long-term Debt
2.88MUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-516.96MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
112.05MUSDvs all stocks (USD)
52-Week Low
1.26USDUpdated Jul 18, 202652-Week High
4.23USDUpdated Jul 18, 202652-Week Change
72.56%vs all stocks
Beta
3.26xvs all stocks
50-Day MA
3.31USDUpdated Jul 18, 2026200-Day MA
2.84USDUpdated Jul 18, 2026Avg 10-Day Volume
5.65MSharesUpdated Jul 18, 2026Avg 30-Day Volume
5.80MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-1.78USDUpdated Jul 18, 2026Other Income / Expense
358.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.95Altman Z-Score: -1.83
Financial Health
Altman Z-Score -1.83: distress zoneCritical
Altman Z-Score: -1.83
Low earnings qualitySignificant
Earnings Quality Score: -0.73
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Kawin Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ocugen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Fengyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shaanxi Panlong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guanhao Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yungshin Global Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Editas Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guizhou Yibai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Leadman Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Hanbon Science & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Nanfeng Ventilator Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Doushen Beijing Education Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Jinlihua Electric Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated